Zobrazeno 1 - 10
of 150
pro vyhledávání: '"Jason Fangusaro"'
Autor:
Jason Fangusaro, Maria Giuseppina Cefalo, Maria Luisa Garré, Lynley V. Marshall, Maura Massimino, Bouchra Benettaib, Noha Biserna, Jennifer Poon, Jackie Quan, Erin Conlin, John Lewandowski, Mathew Simcock, Neelum Jeste, Darren R. Hargrave, François Doz, Katherine E. Warren
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
IntroductionTreatment of recurrent primary pediatric brain tumors remains a major challenge, with most children succumbing to their disease. We conducted a prospective phase 2 study investigating the safety and efficacy of pomalidomide (POM) in child
Externí odkaz:
https://doaj.org/article/d395641b01c342e29099d2b5c09c697d
Autor:
Andrew DJ. Pearson, Carl Allen, Jason Fangusaro, Caroline Hutter, Olaf Witt, Susan Weiner, Gregory Reaman, Mark Russo, Pratiti Bandopadhayay, Sama Ahsan, Amy Barone, Elly Barry, Teresa de Rojas, Michael Fisher, Elizabeth Fox, Julia Glade Bender, Lia Gore, Darren Hargrave, Doug Hawkins, Brent Kreider, Abraham J. Langseth, Giovanni Lesa, Franca Ligas, Marcelo Marotti, Lynley V. Marshall, Kahina Nasri, Koen Norga, Karsten Nysom, Alberto Pappo, Gianluca Rossato, Nicole Scobie, Malcolm Smith, Elliot Stieglitz, Brenda Weigel, Amy Weinstein, Ruth Viana, Dominik Karres, Gilles Vassal
Publikováno v:
European Journal of Cancer. 177:120-142
Autor:
Peter M K de Blank, Andrea M Gross, Srivandana Akshintala, Jaishri O Blakeley, Gideon Bollag, Ashley Cannon, Eva Dombi, Jason Fangusaro, Bruce D Gelb, Darren Hargrave, AeRang Kim, Laura J Klesse, Mignon Loh, Staci Martin, Christopher Moertel, Roger Packer, Jonathan M Payne, Katherine A Rauen, Jonathan J Rios, Nathan Robison, Elizabeth K Schorry, Kevin Shannon, David A Stevenson, Elliot Stieglitz, Nicole J Ullrich, Karin S Walsh, Brian D Weiss, Pamela L Wolters, Kaleb Yohay, Marielle E Yohe, Brigitte C Widemann, Michael J Fisher
Publikováno v:
Neuro Oncol
Neuro-Oncology, vol 24, iss 11
Neuro-Oncology, vol 24, iss 11
The wide variety of clinical manifestations of the genetic syndrome neurofibromatosis type 1 (NF1) are driven by overactivation of the RAS pathway. Mitogen-activated protein kinase kinase inhibitors (MEKi) block downstream targets of RAS. The recent
Autor:
Erin S. Murphy, Girish Dhall, Jason Fangusaro, Ute Bartels, Maryam Fouladi, Dennis Shaw, Soumen Khatua, Chris Williams Hughes, Ashok Panigraphy, Myrsini Ioakeim-Ioannidou, Mark Souweidane, David Morris, Amar Gajjar, Shengjie Wu, Arzu Onar-Thomas, Daphne A. Haas-Kogan, Shannon M. MacDonald
Publikováno v:
Int J Radiat Oncol Biol Phys
PURPOSE: Children’s Oncology Group study ACNS1123 tested the efficacy of reduced dose and field of radiation therapy (RT) for patients with localized nongerminomatous germ cell tumors (NGGCT) who achieved a complete (CR) or partial response (PR) to
Autor:
Vidya Gopalakrishnan, Laurence Cooper, Alvaro Laureano, Lars Riedemann, Martin Hasselblatt, Tobey MacDonald, Irene B. Helenowski, Stewart Goldman, Veena Rajaram, Jason Fangusaro, Pete Taylor
PDF file, 169KB, Measurement of Syn1 expression following SAHA treatment of murine NSC-M and NSC-MR cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40fd183ec3a5ff7ad5b0370f34979771
https://doi.org/10.1158/1535-7163.22497334
https://doi.org/10.1158/1535-7163.22497334
Autor:
Vidya Gopalakrishnan, Laurence Cooper, Alvaro Laureano, Lars Riedemann, Martin Hasselblatt, Tobey MacDonald, Irene B. Helenowski, Stewart Goldman, Veena Rajaram, Jason Fangusaro, Pete Taylor
PDF file, 73KB.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75431aab145fde29960e4441d1d0e0ac
https://doi.org/10.1158/1535-7163.22497331.v1
https://doi.org/10.1158/1535-7163.22497331.v1
Autor:
Vidya Gopalakrishnan, Laurence Cooper, Alvaro Laureano, Lars Riedemann, Martin Hasselblatt, Tobey MacDonald, Irene B. Helenowski, Stewart Goldman, Veena Rajaram, Jason Fangusaro, Pete Taylor
Medulloblastoma is a malignant pediatric brain tumor. Current treatment following patient stratification into standard and high-risk groups using clinical features has improved survival. However, a subset of patients with standard risk features have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::916b05f8cc855609cff1f414e17805bc
https://doi.org/10.1158/1535-7163.c.6535585
https://doi.org/10.1158/1535-7163.c.6535585
Autor:
Vidya Gopalakrishnan, Laurence Cooper, Alvaro Laureano, Lars Riedemann, Martin Hasselblatt, Tobey MacDonald, Irene B. Helenowski, Stewart Goldman, Veena Rajaram, Jason Fangusaro, Pete Taylor
PDF file, 338KB, Table1A. Overview of Database; Table 1B. Event Free Survival (EFS); Table 1C. Overall Survival (OS).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::426aff850841de23124537f2a986cc7f
https://doi.org/10.1158/1535-7163.22497325
https://doi.org/10.1158/1535-7163.22497325
Publikováno v:
Cancers; Volume 15; Issue 7; Pages: 2109
Background: Understanding the effect of selumetinib on FASI may help elucidate the biology, proliferative potential, and role in neurocognitive changes for these NF1-associated lesions. Methods: Patients with NF1-associated LGG and FASI treated with
Autor:
Benjamin Mizukawa, Vanessa A Fabrizio, Neerav Shukla, Sharon M. Castellino, Daniel S. Wechsler, Marilyn Winchester, Nancy Bouvier, Ahmet Zehir, Brian Turpin, David S. Shulman, Himalee S. Sabnis, Jason Fangusaro, Julia Glade-Bender, Steven G. DuBois, Chanta Whitlow, Laura Agresta
Publikováno v:
J Clin Oncol
PURPOSE The US Food and Drug Administration–expanded access program (EAP) uses a single patient use (SPU) mechanism to provide patient access to investigational agents in situations where no satisfactory or comparable therapy is available. Genomic